Companies /Healthcare

Collegium Pharmaceutical Inc

NASDAQ: COLL Drug Manufacturers - Specialty & Generic
$22.09
▼ $0.00 (−0.01%) today
Markets open · 11:00am ET

COLL at a Glance

Valuation
Market cap
$719.2M
P/E ratio
17.4
Profitability
Revenue (TTM)
$808.2M
Profit margin
5.9%
EPS (TTM)
$1.27
Price
52-week range
$21 – $51
Street target
$49.00
Earnings
Next report
Nov 5, 2026

Headquartered in Stoughton, MA Fiscal year ends December NASDAQ: COLL collegiumpharma.com

About Collegium Pharmaceutical

Collegium Pharmaceutical is a biopharmaceutical company focused on developing and commercializing medicines for people living with complex central nervous system and pain conditions. The company's ADHD portfolio includes JORNAY PM (methylphenidate HCl), an evening-dosed stimulant for ADHD, and AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a prodrug-based stimulant combining fast and long-acting components in a single capsule, acquired from Corium Therapeutics in May 2026 with patent protection through 2037. The company's pain portfolio consists of Belbuca (buprenorphine buccal film) for chronic pain, Xtampza ER (abuse-deterrent extended-release oxycodone), and the Nucynta Franchise (tapentadol), including authorized generic versions. Collegium employs formulation and delivery innovation across its product lines, with a unified commercial platform serving both neuropsychiatry/pediatric and pain management healthcare providers. The company trades on Nasdaq under the ticker COLL and had approximately $2.1 billion in total assets as of June 30, 2026, with significant intangible assets and goodwill from its acquisition strategy. Updated

COLL Coverage

Frequently Asked Questions

What does Collegium Pharmaceutical do?

Collegium Pharmaceutical is a biopharmaceutical company focused on developing and commercializing medicines for people living with complex central nervous system and pain conditions.

What is the COLL stock price target?

The Wall Street consensus 12-month price target for COLL is $49.00.